Article Text

AB0719 2-Year Incidence of New Immune-Mediated Inflamatory Diseases in Patients with Spondyloarthritis. the Aquiles Study
  1. R. García-Vicuna1,
  2. P. Zarco2,
  3. C.M. Gonzalez3,
  4. A. Rodríguez de la Serna4,
  5. E. Peiro5,
  6. I. Mateo6,
  7. L. Linares7,
  8. J. Calvo8,
  9. S. Fernandez9,
  10. L. Cea-Calvo9,
  11. M.J. Arteaga9,
  12. I. Marín-Jiménez10,
  13. F. Vanaclocha11
  14. on behalf of AQUILES Investigators
  1. 1Dpt of Rheumatology, La Princesa Hospital, IISP
  2. 2Dpt of Rheumatology, Alcorcon Hospital Foundation
  3. 3Dpt of Rheumatology, Gregorio Marañόn Hospital, Madrid
  4. 4Dpt of Rheumatology, Sant Pau Hospital, Barcelona
  5. 5Marqués de Valdecilla Hospital, Santander
  6. 6Dpt of Rheumatology, 12 de Octubre Hospital, Madrid
  7. 7Dpt of Rheumatology, Virgen de la Arrixaca Hospital, Murcia
  8. 8Dpt of Rheumatology, Reina Sofía Hospital, Cόrdoba
  9. 9Medical Affairs, Merck Sharp & Dohme, Spain
  10. 10Dpt of Gastroenterology, Gregorio Marañόn Hospital
  11. 11Dpt. of Dermatology, 12 de Octubre Hospital, Madrid, Spain


Background Patients with spondyloarthritis (SpA) frequently show other immune-mediated inflammatory diseases (IMID)

Objectives To describe the 2-year incidence of new diagnoses of IMID in patients with SpA recruited for the AQUILES study

Methods AQUILES was a prospective observational study on 3 independent cohorts of patients aged ≥18 years-old with SpA, inflammatory bowel disease (IBD) or psoriasis recruited from rheumatology, IBD and dermatology offices from 15 hospitals in Spain. Patients were followed for 2 years. In the SpA cohort, the diagnosis of new IMID was based on reports from gastroenterologists (IBD), dermatologists (psoriasis) or ophthalmologists (uveitis)

Results A total of 513 patients with SpA completed the 2-year follow-up (mean age: 48 years-old; 37.5% females, 62.5% males). Median duration of disease was 7.8 years. The diagnoses at baseline were: ankylosing spondylitis (AS) (n=285), psoriatic arthritis (PsA) (n=130), enteropathic arthritis (n=13), undifferentiated arthritis (n=83) and others (n=2). At baseline, 45% had other IMID (4.9% IBD; 28.7% psoriasis; 14.6% uveitis). During the 2-year period, 22 new diagnoses of incident IMID were recorded (cumulative incidence: 4.3%, 95% CI: 2.4-6.1; incidence rate: 17 cases per 10,000 patients-year). The predominant incident IMID was uveitis (16 cases, cumulative incidence 3.1%, 95% CI: 1.5-4.7). In the subgroup with AS, there were 16 new cases of IMID (5.6%; 13 of them uveitis [4.6%], 1 IBD [0.4%] and 2 psoriasis [0.8%]). In patients with PsA only 2 patients developed a new IMID (2 new diagnoses of psoriasis [1.5%]). In those with undifferentiated SpA, there were 2 new diagnoses of uveitis (2.4%) and 1 psoriasis (1.2%), and 1 patient with enteropathic arthritis developed uveitis. There were no differences in the incidence by patient's age, gender, duration of disease, extra-articular manifestations or family history of SpA, and the multivariate analysis identified the diagnosis of AS as the only predictor of development of new IMID (OR: 3.5 [1.0-15.3, p=0.049] versus psoriatic arthritis)

Conclusions In SpA patients recruited for the AQUILES study, the 2-year cumulative incidence of new IMID was 4.3%, mostly due to new patients with diagnosis of uveitis in patients with AS. Diagnosis of AS at baseline was the only predictor for the development of a new IMID

Acknowledgements The AQUILES study was funded by Merck Sharp & Dohme of Spain. The authors thank the investigators for the recruitment and follow-up of patients

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.3090

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.